Journal
NATURE REVIEWS IMMUNOLOGY
Volume 9, Issue 10, Pages 704-716Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nri2635
Keywords
-
Categories
Funding
- US National Institutes of Health (NIH) [5R01CA105216, 1R01CA120409, 5P01CA066726, 1U19AI082628]
- US NIH [2R01HL56067, R01AI34495, R01CA72669, P01CA142106, P01AI056299, P30AI045008, R01AI057838, R01CA113783, R41CA130547, U19AI066290, U19AI082628, P01AI080192]
- Leukemia and Lymphoma Translational Research
- JDRF Center on Cord Blood Therapies for Type 1 Diabetes
- NATIONAL CANCER INSTITUTE [P01CA065493, P01CA142106, R01CA113783, R01CA072669, R41CA130547, R01CA105216, R01CA120409, P01CA066726] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056067] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI045008, U19AI066290, U19AI082628, R01AI057838, P01AI080192, R01AI034495, P01AI056299] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Cell-based therapies with various lymphocyte subsets hold promise for the treatment of several diseases, including cancer and disease resulting from inflammation and infection. The ability to genetically engineer lymphocyte subsets has the potential to improve the natural immune response and correct impaired immunity. In this Review we focus on the lymphocyte subsets that have been modified genetically or by other means for therapeutic benefit, on the technologies used to engineer lymphocytes and on the latest progress and hurdles in translating these technologies to the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
